Literature DB >> 20170907

Exogenous allogenic fragmented double-stranded DNA is internalized into human dendritic cells and enhances their allostimulatory activity.

Ekaterina A Alyamkina1, Evgenia V Dolgova, Anastasia S Likhacheva, Vladimir A Rogachev, Tamara E Sebeleva, Valeriy P Nikolin, Nelly A Popova, Elena V Kiseleva, Konstantin E Orishchenko, Ludmila V Sakhno, Evgeniy L Gel'fgat, Alexandr A Ostanin, Elena R Chernykh, Stanislav N Zagrebelniy, Sergey S Bogachev, Mikhail A Shurdov.   

Abstract

Exogenous allogenic DNA as nucleosome-free fragments reaches main cellular compartments (cytoplasm, nucleus) of human dendritic cells and deposits in the nuclear interchromosomal space without visibly changing in linear size. The presence of such allogenic fragmented DNA in medium in which human dendritic cells are cultured produces an enhancement of their allostimulatory activity. This enhancement is comparable to that produced by the standard maturation stimulus lipopolysaccharide Escherichia coli. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20170907     DOI： 10.1016/j.cellimm.2010.01.005

Source DB:  PubMed          Journal:  Cell Immunol        ISSN： 0008-8749            Impact factor:   4.868


  8 in total

1.  Chronometric Administration of Cyclophosphamide and a Double-Stranded DNA-Mix at Interstrand Crosslinks Repair Timing, Called "Karanahan" Therapy, Is Highly Efficient in a Weakly Immunogenic Lewis Carcinoma Model.

Authors:  Vera Ruzanova; Anastasia Proskurina; Yaroslav Efremov; Svetlana Kirikovich; Genrikh Ritter; Evgenii Levites; Evgenia Dolgova; Ekaterina Potter; Oksana Babaeva; Sergey Sidorov; Oleg Taranov; Alexandr Ostanin; Elena Chernykh; Sergey Bogachev
Journal:  Pathol Oncol Res       Date:  2022-05-27       Impact factor: 2.874

2.  A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation.

Authors:  Ekaterina A Alyamkina; Valeriy P Nikolin; Nelly A Popova; Evgenia V Dolgova; Anastasia S Proskurina; Konstantin E Orishchenko; Yaroslav R Efremov; Elena R Chernykh; Alexandr A Ostanin; Sergey V Sidorov; Dmitriy M Ponomarenko; Stanislav N Zagrebelniy; Sergey S Bogachev; Mikhail A Shurdov
Journal:  Genet Vaccines Ther       Date:  2010-11-01

3.  Combination of cyclophosphamide and double-stranded DNA demonstrates synergistic toxicity against established xenografts.

Authors:  Ekaterina A Alyamkina; Valeriy P Nikolin; Nelly A Popova; Alexandra M Minkevich; Artem V Kozel; Evgenia V Dolgova; Yaroslav R Efremov; Sergey I Bayborodin; Oleg M Andrushkevich; Oleg S Taranov; Vladimir V Omigov; Vladimir A Rogachev; Anastasia S Proskurina; Evgeniy I Vereschagin; Elena V Kiseleva; Maria V Zhukova; Alexandr A Ostanin; Elena R Chernykh; Sergey S Bogachev; Mikhail A Shurdov
Journal:  Cancer Cell Int       Date:  2015-03-19       Impact factor: 5.722

4.  Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer.

Authors:  Anastasia S Proskurina; Tatiana S Gvozdeva; Ekaterina A Alyamkina; Evgenia V Dolgova; Konstantin E Orishchenko; Valeriy P Nikolin; Nelly A Popova; Sergey V Sidorov; Elena R Chernykh; Alexandr A Ostanin; Olga Y Leplina; Victoria V Dvornichenko; Dmitriy M Ponomarenko; Galina S Soldatova; Nikolay A Varaksin; Tatiana G Ryabicheva; Peter N Uchakin; Stanislav N Zagrebelniy; Vladimir A Rogachev; Sergey S Bogachev; Mikhail A Shurdov
Journal:  BMC Cancer       Date:  2015-03-13       Impact factor: 4.430

5.  Properties of internalization factors contributing to the uptake of extracellular DNA into tumor-initiating stem cells of mouse Krebs-2 cell line.

Authors:  Evgeniya V Dolgova; Ekaterina A Potter; Anastasiya S Proskurina; Alexandra M Minkevich; Elena R Chernych; Alexandr A Ostanin; Yaroslav R Efremov; Sergey I Bayborodin; Valeriy P Nikolin; Nelly A Popova; Nikolay A Kolchanov; Sergey S Bogachev
Journal:  Stem Cell Res Ther       Date:  2016-05-25       Impact factor: 6.832

6.  Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen.

Authors:  Anastasia S Proskurina; Tatiana S Gvozdeva; Ekaterina A Potter; Evgenia V Dolgova; Konstantin E Orishchenko; Valeriy P Nikolin; Nelly A Popova; Sergey V Sidorov; Elena R Chernykh; Alexandr A Ostanin; Olga Y Leplina; Victoria V Dvornichenko; Dmitriy M Ponomarenko; Galina S Soldatova; Nikolay A Varaksin; Tatiana G Ryabicheva; Peter N Uchakin; Vladimir A Rogachev; Mikhail A Shurdov; Sergey S Bogachev
Journal:  BMC Cancer       Date:  2016-08-18       Impact factor: 4.430

7.  Defective Regulation of Membrane TNFα Expression in Dendritic Cells of Glioblastoma Patients Leads to the Impairment of Cytotoxic Activity against Autologous Tumor Cells.

Authors:  Tamara Tyrinova; Olga Leplina; Sergey Mishinov; Marina Tikhonova; Evgeniya Dolgova; Anastasiya Proskurina; Vyacheslav Stupack; Sergey Bogachev; Alexander Ostanin; Elena Chernykh
Journal:  Int J Mol Sci       Date:  2020-04-21       Impact factor: 5.923

8.  Identification of the xenograft and its ascendant sphere-forming cell line as belonging to EBV-induced lymphoma, and characterization of the status of sphere-forming cells.

Authors:  Evgeniya V Dolgova; Daria D Petrova; Anastasia S Proskurina; Genrikh S Ritter; Polina E Kisaretova; Ekaterina A Potter; Yaroslav R Efremov; Sergey I Bayborodin; Tatiana V Karamysheva; Margarita V Romanenko; Sergey V Netesov; Oleg S Taranov; Aleksandr A Ostanin; Elena R Chernykh; Sergey S Bogachev
Journal:  Cancer Cell Int       Date:  2019-05-06       Impact factor: 5.722
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.